Published in
Elsevier, Annals of Oncology, (31), p. S16, 2020
DOI: 10.1016/j.annonc.2020.03.139
Links
Tools
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Journal article published in 2020 by
W. Jacot,
H. M. Savage,
S. Dent,
J. Cortés,
Y.-H. Im,
V. C. Dieras,
N. Harbeck,
I. E. Krop,
J. Chen 
,
E. Sokol,
F. Schimmoller,
J. Hsu,
M. De Laurentiis,
T. R. Wilson
,
E. Sokol,
F. Schimmoller,
J. Hsu,
M. De Laurentiis,
T. R. Wilson
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 